Huawei to launch 5G Mate X smartphone in China, finally
Shanghai
HUAWEI Technologies Co Ltd started taking orders on Wednesday in China for its eagerly awaited foldable smartphone, as it ramps up marketing at home to make up for weak overseas sales amid US trade sanctions.
The launch of the 5G Mate X smartphone has been delayed twice this year, as Huawei, the world's No2 smartphone maker, was forced to deal with tech supply disruptions caused by a US trade blacklist imposed on the firm in May.
The move has dealt a blow to Huawei's smartphone sales in Europe, its key overseas market, but the company saw its third-quarter revenue rising 27 per cent thanks to solid sales in China and higher shipments of models launched before the May ban.
The new smartphone, a competitor to Samsung Electronics Co's Galaxy Fold which went on sale last month, will be launched officially on Nov 15 in China at prices starting from 16,999 yuan (S$3,230), a Huawei spokesman said. Its global launch plan remains under review, Huawei said.
Washington alleges that Huawei, also the world's biggest telecoms gear maker, is a national security risk as its equipment could be used by Beijing to spy - something the Shenzhen-based company has repeatedly denied.
The ban has meant that Huawei has not been able to license the latest version of Android from Google, the Alphabet unit, which has impacted its latest Mate 30 smartphone range that it launched in September.
He Gang, head of Huawei's mobile phone division, said on Wednesday the company has already sold more than 200 million phones so far in 2019, hitting that milestone more than two months earlier than it did in 2018.
Huawei's 5G Mate X was originally set for a June launch but the company delayed it, saying that it was running certification tests with various carriers. REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue